ODAC To Assess Safety Of Lilly’s Evista As Breast Cancer Preventative

FDA is seeking advice from its Oncologic Drugs Advisory Committee on expectations for efficacy and risk when dealing with a drug to prevent breast cancer.

More from Archive

More from Pink Sheet